Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with... Purpose This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Pacli- taxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). Methods One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous 2 2 infusions of PTX at 135 mg/m and OXA at 85 mg/m on day 1 every 14 days. Results Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measur- able lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9–52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5–87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30– 7.30 months) and the median overall survival was 11.5 months (95% CI 9.08–13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients. Conclusions Combination chemotherapy with PTX and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Loading next page...
 
/lp/springer_journal/combination-chemotherapy-with-paclitaxel-and-oxaliplatin-as-first-line-UFJLPySLU0
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
D.O.I.
10.1007/s00280-018-3576-x
Publisher site
See Article on Publisher Site

Abstract

Purpose This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Pacli- taxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC). Methods One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous 2 2 infusions of PTX at 135 mg/m and OXA at 85 mg/m on day 1 every 14 days. Results Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measur- able lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9–52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5–87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30– 7.30 months) and the median overall survival was 11.5 months (95% CI 9.08–13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients. Conclusions Combination chemotherapy with PTX and

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: Apr 4, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off